Lipid and Lipoprotein Metabolism in Chronic Kidney Disease

Journal of Renal Nutrition

Volumn 19, Issue 1, 2009, Pages 73-77

  Kaysen, George A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; METABOLISM; MORTALITY; PHYSIOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; RISK FACTORS; TRIGLYCERIDES;

EID: 58149097085     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2008.10.011     Document Type: Article

References (43)

1. NIH/NIDDK/Division of Kidney. Urologic & Hematologic Diseases: USRDS 17th annual report (2005), NIH/NIDDK, Washington, DC 128-129
2. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
3. Iseki K., Yamazato M., Tozawa M., et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61 (2002) 1887-1893
4. Koch M., Kutkuhn B., Grabensee B., et al. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 12 (1997) 2603-2611
5. Shoji T., Nishizawa Y., Kawagishi T., et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9 (1998) 1277-1284
6. Stompor T., Pasowicz M., Sullowicz W., et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 41 (2003) 111-203
7. Muntner P., Coresh J., Smith J.C., et al. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int 58 (2000) 293-301
8. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290 (2006) F262-F272
9. Deighan C.J., Caslake M.J., McConnell M., et al. Related Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35 (2000) 852-862
10. Ikewaki K., Schaefer J.R., Frischmann M.E., et al. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2615-2622
11. Dautin G., Soltani Z., Ducloux D., et al. Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int 72 (2007) 871-878
12. Wakabayashi Y., Okubo M., Shimada H., et al. Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment. Metabolism 36 (1987) 815-820
13. Hirano T., Sakaue T., Misaki A., et al. Very low-density lipoprotein-apoprotein C I is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 63 (2003) 2171-2177
14. Mekki K., Bouchenak M., Remaoun M., et al. Effect of long-term hemodialysis on plasma lecithin:cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study. Med Sci Monit 10 (2004) CR439-CR446
15. Berbee J.F., van der Hoogt C.C., Sundararaman D., et al. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 46 (2005) 297-306
16. van der Hoogt C.C., Berbee J.F., Espirito Santo S.M., et al. Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice. Biochim Biophys Acta 1761 (2006) 213-220
17. Miida T., Miyazaki O., Hanyu O., et al. LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 14 (2003) 732-738
18. Welty F.K., Lichtenstein A.H., Barrett P.H., et al. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 24 (2004) 1703-1707
19. Ikewaki K., Schaefer J.R., Frischmann M.E., et al. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2615-2622
20. Kobayashi S., Maesato K., Moriya H., et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 45 (2005) 275-280
21. Anderwald C., and Roden M. Adipotoxicity and the insulin resistance syndrome. Pediatr Endocrinol Rev 1 (2004) 309-310
22. Alabakovska S.B., Todorova B.B., Labudovic D.D., et al. Related LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem 35 (2002) 211-216
23. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
24. Kurella M., Lo J.C., and Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16 (2005) 2134-2140
25. Muntner P., He J., Astor B.C., et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 16 (2005) 529-538
26. Lo J.C., Go A.S., Chandra M., et al. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis 50 (2007) 552-558
27. Quintao E.C., Medina W.L., and Passarelli M. Related Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 16 (2000) 237-250
28. Elshourbagy N.A., Boguski M.S., et al. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci USA 82 (1985) 8242-8246
29. Bayés B., Pastor M.C., Bonal J., et al. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant 21 (2006) 984-990
30. Rozek L.S., Hatsukami T.S., Richter R.J., et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res 46 (2005) 1888-1895
31. Morena M., Cristol J.P., Dantoine T., et al. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 15 (2000) 389-395
32. Quintao E.C., Medina W.L., and Passarelli M. Related reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 16 (2000) 237-250
33. Sparks D.L., Davidson W.S., Lund-Katz S., et al. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 270 (1995) 26910-26917
34. Ooi E.M., Watts G.F., Farvid M.S., et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res 13 (2005) 1008-1016
35. Pietzsch J., Julius U., Nitzsche S., et al. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47 (1998) 1928-1934
36. Rye K.A., Clay M.A., and Barter P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145 (1999) 227-238
37. Mendez A.J., Perez G.O., and Hsia S.L. Defect in cholesteryl ester transport in serum of patients with uremia receiving maintenance hemodialysis: increased inhibitor activity for cholesteryl ester transfer. J Lab Clin Med 111 (1988) 677-683
38. Lackner C., Boerwinkle E., Leffert C.C., et al. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87 (1991) 2153-2161
39. Kronenberg F., Kuen E., Ritz E., et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11 (2000) 105-115
40. De Sain-Van Der Velden M.G., Reijngoud D.J., et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 9 (1998) 1474-1481
41. Kuboyama M., Ageta M., Ishihara T., et al. Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. J Atheroscler Thromb 10 (2003) 283-289
42. Frischmann M.E., Kronenberg F., Trenkwalder E., et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 71 (2007) 1036-1043
43. Longenecker J.C., Klag M.J., Marcovina S.M., et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 16 (2005) 1794-1802